The effects of methotrexate on interleukin 1 in patients with rheumatoid arthritis

J Rheumatol. 1992 Nov;19(11):1678-82.


The effect of methotrexate (MTX) treatment on patients with rheumatoid arthritis on interleukin 1 (IL-1) was evaluated. Eight patients received a weekly MTX dose of 7.5 mg for 6 weeks; none received concomitant corticosteroids. Peripheral blood was obtained 1 day before and 1 day after their weekly MTX dose at Week 1 and 6, isolated monocytes stimulated ex vivo with 1 mg/ml zymosan for 18 h and IL-1 measured by bioassay. Serum and plasma IL-1 levels were measured by immunoassay. Four patients manifested a sharp decrease in IL-1 production 6 weeks after MTX administration associated with a decrease in the number of painful but not swollen joints. No effect on blood levels was observed. Our results suggest that MTX may affect IL-1 production and IL-1 mediated events in some patients.

Publication types

  • Clinical Trial

MeSH terms

  • Administration, Oral
  • Aged
  • Arthritis, Rheumatoid / blood*
  • Arthritis, Rheumatoid / drug therapy*
  • Arthritis, Rheumatoid / epidemiology
  • Dose-Response Relationship, Drug
  • Female
  • Humans
  • Interleukin-1 / blood*
  • Interleukin-1 / metabolism
  • Male
  • Methotrexate / administration & dosage
  • Methotrexate / therapeutic use*
  • Middle Aged
  • Monocytes / metabolism
  • Prospective Studies
  • Time Factors
  • Zymosan / pharmacology


  • Interleukin-1
  • Zymosan
  • Methotrexate